[PDF] Top 20 Interstitial lung disease in systemic sclerosis: where do we stand?
Has 10000 "Interstitial lung disease in systemic sclerosis: where do we stand?" found on our website. Below are the top 20 most common "Interstitial lung disease in systemic sclerosis: where do we stand?".
Interstitial lung disease in systemic sclerosis: where do we stand?
... of lung structure for monitoring parenchymal damage [28] and a good correlation with PFTs has been shown ...in lung ultrasound (LUS) as a fast and noninvasive method with no risk of radiation exposure [26, ... See full document
9
Does high-dose extended course cyclophosphamide and methylprednisolone pulse therapy have a role in the management of systemic sclerosis-related interstitial lung disease?
... © The Author 2016. Published by Oxford University Press on behalf of the British Society for Rheumatology. This is a pre-copyedited, author-produced PDF of an article accepted for publication in Rheumatology following ... See full document
8
<p>Interstitial Lung Disease in Systemic Sclerosis: Focus on Early Detection and Intervention</p>
... Abstract: Systemic sclerosis (SSc) is a progressive and often devastating disease characterized by autoimmune dysfunction, vasculopathy, and fi ...brosis. Interstitial lung ... See full document
25
Pulmonary function tests as outcomes for systemic sclerosis interstitial lung disease
... The MEDLINE (PubMed), Embase (Ovid), and Web of Science databases were searched on July 05, 2016 to identify all potentially relevant studies since January 1949. ClinicalTrials.gov and the World Health Organization (WHO) ... See full document
16
Low dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study
... the lung characterized by ground-glass (Figure ...vanced lung disease – treating patients at an earlier stage could be more rewarding, as suggested by the lack of effect of imatinib on established ... See full document
10
Immunosuppression for interstitial lung disease in systemic sclerosis
... Rituximab (RTX) is a chimeric monoclonal antibody directed against CD20, an antigen on the surface of B lymphocytes [36]. Since elevated levels of B lymphocytes have been described in the lung of patients with ... See full document
8
<p>Epidemiology of systemic sclerosis and systemic sclerosis-associated interstitial lung disease</p>
... of disease, with approximately 25% of the patients developing sig- ni fi cant pulmonary involvement within 3 years of SSc ...10 Interstitial lung disease (ILD) constitutes one of the most ... See full document
17
Predicting Lung Function Decline with Serum Pneumoproteins: A Case Control Study
... of lung function decline in systemic sclerosis (SSc) are ...damage. We aimed to test whether levels can predict rapid lung function decline in ...age, disease duration, gender, ... See full document
6
Clinical significance of antibodies to Ro52/TRIM21 in systemic sclerosis
... of disease severity recorded on a numeric rating scale ranging from 0, representing no dis- ease, to 10, representing most-severe ...disease. Disease severity also is measured by using a modified ... See full document
9
Contribution of pulmonary function tests (PFTs) to the diagnosis and follow up of connective tissue diseases
... important disease considered in Scleroderma Spectrum Disorders (SSDs) is Systemic Sclerosis ...The disease affects about 1 out of 10,000 persons [27] and is characterized by fibrosis of the ... See full document
11
Personalised medicine in interstitial lung diseases
... of disease severity, although no specific microbe was associated with the rate of progression ...rapid disease progression in patients with IPF ...pulmonary disease and ...the lung microbiome ... See full document
12
The theranostic promise for Neuroendocrine Tumors in the late 2010s - Where do we stand, where do we go?
... For instance, current international guidelines recommend to restrict PRRT to WHO Grade 1/2 (Ki67 ≤ 20%) NET patients and thus, the majority of the performed studies to date (including the NETTER-1 trial) are limited to ... See full document
13
Quality assessment in surgery: where do we stand now and where should we be heading?
... outcome. The National Surgical Quality Improvement Pro- gram (NSQIP) in the USA was established in the early nineties of the previous century to record risk-adjusted surgical mor- bidity, rate hospital quality, and ... See full document
7
Disease modifying treatments and symptomatic drugs for cognitive impairment in multiple sclerosis: where do we stand?
... RRMS where patients were randomized to receive GA (20 mg sub- cutaneously every day) or placebo ...Multiple Sclerosis) and SENTINEL (Safety and Efficacy of Natalizumab in Combination with Inter- feron ... See full document
7
Immunosenescence and Cytomegalovirus: where do we stand after a decade?
... far we are able to assess the clinical impact of these factors using epidemiological approaches, longitudinal and cross-sectional studies was to be discussed, as well as the mechanisms responsible for such ... See full document
5
Managing adult Fontan patients: where do we stand?
... In lung biopsies taken at the time of bidirectional Glenn procedure, patients who subsequently struggled following Fontan completion were demonstrated to have muscularised distal pulmonary arteries; this was a ... See full document
13
Hadronic Interactions and Air Showers: Where Do We Stand?
... One contribution to the elasticity is the diffractive dis- sociation. Diffraction is a special case of interaction where no central ladder is produced and there is only some mo- mentum exchange between excited ... See full document
8
The HIV self-testing debate: where do we stand?
... 1). We included articles that focused exclusively on HST as “a form of testing in which an individual collects his or her own sample; performs a simple, rapid laboratory test; and is, therefore, the first to know ... See full document
7
Rate-Control or Rhythm-Contol: Where do we stand?
... drug are burdened by a substantial risk of ventricular arrhythmias. A patients treated with rhythm control approach have not an increased risk of haemorragies but an increased risk of sudden death. The contrary may be ... See full document
9
Where Do We Stand on High Heels in 2018? An Audit
... Very few respondents (3%) said that high heels were their most common ca- sual shoe, but 22% would usually wear them for a meal out, and 80% for a ro- mantic date. For a smart casual party, 37% would usually wear high ... See full document
10
Related subjects